Prosthetic Heart Valves: Echocardiographic Assessment

Prosthetic heart valves fall into two broad categories — bioprosthetic (tissue) and mechanical — each with distinct durability, thrombotic risk, and echocardiographic assessment considerations. This tutorial covers valve types, the physiologic principles that make prosthetic valve Doppler assessment genuinely different from native valve assessment, position-specific echocardiographic evaluation, and the valve selection and anticoagulation guidance that determines how patients are actually managed after implantation. It draws primarily on the 2024 ASE guideline for the evaluation of prosthetic valve function with cardiovascular imaging — which explicitly replaces the 2009 ASE prosthetic valve recommendations — alongside the 2020 ACC/AHA and 2025 ESC/EACTS valvular heart disease guidelines for the broader management questions. Right-sided replacement for carcinoid heart disease is a genuine example of how this choice evolves — early practice favored mechanical valves out of concern for carcinoid affecting bioprosthetic tissue, though recent evidence shows comparable outcomes between the two.

Bioprosthetic Valves

Types

• Autograft (self-to-self) — the patient’s own pulmonic valve transplanted into the aortic position (the Ross procedure). Both current VHD guidelines describe this as a reasonable alternative to a mechanical valve in young patients, when performed at an experienced center with dedicated expertise in the procedure.
• Homograft (allograft) — an aortic valve transplanted from another human donor. Failure rates at 10 to 15 years run around 10–20%.
• Heterograft (xenograft):
  • Porcine — a pig aortic valve mounted on a stent and sewing ring (e.g., Hancock, Carpentier-Edwards, Intact)
  • Bovine pericardium — cow pericardium fashioned into a tri-leaflet valve (e.g., Carpentier-Edwards, Mitroflow)
  • Heterograft failure rates at 10 to 15 years run around 30% — meaningfully higher than homografts.
• Stentless valves, including homografts and autografts, are more likely than stented valves to have minor regurgitant jets — worth remembering before over-reading a small jet as pathologic in this specific valve type.
• Transcatheter (percutaneous) valves — balloon-expandable intra-annular devices (e.g., SAPIEN; Edwards Lifesciences), self-expanding supra-annular valves (e.g., Evolut; Medtronic), and intra-annular valves (Navitor; Abbott). Unlike surgical prostheses, all percutaneous valves are bioprosthetic.

Complications

Modern guidance (VARC-3) organizes prosthetic valve dysfunction into four categories: structural valve deterioration, nonstructural valve dysfunction, endocarditis, and thrombus.

• Structural valve deterioration (SVD) — intrinsic, permanent changes to the valve itself: wear and tear, leaflet disruption, fibrosis, or calcification, and stent or strut fracture or deformation. Valve calcification is the most common cause of bioprosthetic degeneration, seen in about 50% of porcine valves at 5 years and 75% at 8 years — the leaflets and stent are the primary sites affected. See the formal hemodynamic SVD criteria below.
• Nonstructural valve dysfunction — any abnormality not intrinsic to the valve that still causes dysfunction: prosthesis-patient mismatch, paravalvular leak, leaflet entrapment or pannus, inappropriate position or sizing, and dilation of the cardiac chambers after implantation.
• Infective endocarditis — prevalence 1–6%, at any time after surgery. Bioprosthetic infection characteristically originates in the leaflet cusps and may extend to the sewing ring or paravalvular region.
• Mechanical (thrombus) — see below.

Mechanical Valves

Types

• Ball and cage — Starr-Edwards (now rarely used). Typically has a small closing volume and little or no true transvalvular regurgitation.
• Caged disc — Beall (no longer available)
• Tilting disc — Björk-Shiley (withdrawn from the market; small jets where the closed disk meets the housing) and Medtronic-Hall (the same jets, plus one larger central jet through the disk’s pivot hole)
• Bileaflet — the most frequently used design today: central flow, and the least obstructive of the mechanical valve types. Multiple small “washing jets” occur at the sewing ring and centrally where the closed leaflets meet.

Complications

• Thrombus formation — seen in 0.3–8% of prosthetic valves overall. Mechanical valves are inherently more thrombogenic than bioprosthetic valves, though with appropriate anticoagulation the actual thrombosis risk becomes similar between the two. Right-sided valves are 12 to 20 times more vulnerable to thrombosis than left-sided valves — the tricuspid position specifically carries this markedly elevated risk. On echo, thrombus appears as a soft echodensity mass on the valve; on bioprosthetic valves it can instead appear simply as valve thickening.
• Pannus formation — fibrous tissue ingrowth in the periannular region, causing obstruction or regurgitation. Prevalence 0.2–4.5%, occurring equally in mechanical and bioprosthetic valves, but with a threefold higher risk in the mitral position. Pannus can coexist with thrombus.
• Infective endocarditis — in mechanical valves, infection almost always spreads from the sewing ring, producing paravalvular leak, abscess, or extension to adjacent structures. Paravalvular abscess is genuinely common with prosthetic valve endocarditis (56–100%, versus 10–40% with native valve endocarditis), especially in the aortic position; an associated pseudoaneurysm occurs in 7–25% of prosthetic valve endocarditis cases.
• Structural — dehiscence, perivalvular leak, hemolysis (from turbulent flow across a paravalvular defect or a malfunctioning occluder). Dehiscence requiring reoperation or catheter-based intervention occurs in about 4.9% of aortic prosthetic valves versus 2.0% of mitral prosthetic valves. On echo, independent or “rocking” motion of the valve is a sign of dehiscence and is more diagnostic in the aortic position specifically; in the mitral position, increased mobility can be a normal finding (from annular motion or the sewing ring’s location within the left atrium) and needs to be distinguished from true dehiscence by the absence of a paravalvular leak.

Two Concepts That Make Prosthetic Valve Doppler Genuinely Different From Native Valve Doppler

These two principles explain a large share of the apparent complexity in prosthetic valve assessment, and both are frequently the actual explanation when a Doppler finding looks “too abnormal” for the clinical picture.

Physiologic (“Washing Jet”) Regurgitation

Mechanical valves are expected to show small regurgitant jets — this is a normal, designed-in feature, not a sign of dysfunction. Two types occur: a closing volume (retrograde displacement of blood from occluder motion) and true trivial-to-mild regurgitation at the valve’s hinge points. The pattern differs by valve type — the Starr-Edwards has essentially no true regurgitation; the Björk-Shiley has small jets where the closed disk meets the housing; the Medtronic-Hall has those same jets plus one larger central jet through the pivot hole; bileaflet valves have multiple jets at the sewing ring and centrally, arranged in pairs at each pivot point (sometimes dividing into two or three separate “plumes”). These “washing jets” are thought to prevent thrombus formation at sites of stasis within the sewing ring.

The regurgitant fraction from these physiologic jets is usually no more than 10–15%. The color jet itself can appear surprisingly long — up to 5 cm, especially with Medtronic-Hall valves — but stays narrow at its origin. The jets are low-momentum, so color appears homogeneous with aliasing confined to the jet’s base. Jet length is not a reliable indicator of severity for these physiologic jets — a long, narrow, low-momentum jet at a known hinge location is expected, while a broader, higher-momentum jet, or one originating outside the sewing ring (paravalvular), is what actually warrants concern.

Regurgitation is increasingly reported even in normal bioprosthetic valves, largely reflecting improved Doppler sensitivity on current equipment rather than a true increase in valve dysfunction.

Pressure Recovery

Pressure recovery causes Doppler-derived gradients to overestimate the true invasive gradient, and it occurs in two distinct settings:

1. Downstream of any prosthetic valve, as flow re-expands from the valve orifice into the wider chamber beyond it (the aorta, for an aortic prosthesis), velocity and kinetic energy fall and pressure “recovers.” This effect is usually small — except when the downstream chamber itself is small, such as an aorta under 3 cm in diameter.
2. Within the valve itself, specific to bileaflet and caged-ball designs. The smaller central orifice between the tilting disks produces a localized high-velocity jet and a corresponding localized pressure drop that normalizes once the central flow reunites with flow from the two larger lateral orifices. This is not seen with single-tilting-disk or bioprosthetic valves. CW Doppler often records this high-velocity central jet specifically, overestimating the gradient and underestimating EOA relative to invasive measurement — most pronounced in small prostheses with high flow states. TEE can sometimes differentiate the central from the lateral orifice jets in prosthetic mitral valves (in the near field); TTE generally cannot.

In practice, this effect is usually already built into the normal reference values for Doppler velocities, gradients, and DVI by valve type and size, so it doesn’t typically interfere with routine assessment. The practical exception: small bileaflet aortic valves (e.g., 19 mm) with high flow, where differentiating true abnormal function from expected pressure recovery may require further evaluation with fluoroscopy, CT, or TEE. As a valve becomes genuinely more stenotic, echocardiographic and invasive measurements converge and become concordant.

Choosing Between Mechanical and Bioprosthetic: A Guideline Difference Worth Knowing

Valve selection depends on durability, expected hemodynamics, procedural risk, the need for lifelong anticoagulation, and patient preference — but the two current VHD guidelines give meaningfully different specific age thresholds, worth knowing both rather than treating either as the single correct answer:

• ACC/AHA 2020: mechanical valve favored for patients < 50 years (acceptable anticoagulation risk in most compliant, monitored patients); 50–65 years is an acknowledged gray zone of ongoing debate; bioprosthetic reasonable for patients > 65 years to avoid anticoagulation risk.
• ESC 2025: mechanical valve should be considered for patients < 60 years in the aortic position or < 65 years in the mitral position; bioprosthetic should be considered for patients > 65 years (aortic) or > 70 years (mitral) — explicitly position-specific thresholds, both somewhat higher than ACC/AHA’s.

The underlying trade-off both guidelines describe is the same: bioprosthetic valve durability declines with younger implantation age, while mechanical valves trade that durability for a lifelong anticoagulation requirement. ACC/AHA cites a predicted 15-year reoperation risk for structural bioprosthetic deterioration of roughly 22% at age 50, 30% at age 40, and 50% at age 20 — figures that illustrate why age matters so much to this decision, even as the exact cutoff differs slightly between societies.

Antithrombotic Therapy

Mechanical Valves

Mechanical valves require lifelong vitamin K antagonist (VKA) therapy — direct oral anticoagulants (DOACs) and dual antiplatelet therapy are explicitly contraindicated for thromboprophylaxis, confirmed by both guidelines. Without anticoagulation, thromboembolic/valve thrombosis rates are substantial: ESC cites roughly 12% per year for first-generation aortic mechanical valves and 22% per year for first-generation mitral mechanical valves.

Valve / situation	Target INR
Bileaflet or current-generation single-tilting-disk mechanical AVR, no risk factors	2.5
Mechanical AVR with thromboembolic risk factors (AF, prior thromboembolism, LV dysfunction, hypercoagulable state) or an older-generation prosthesis (e.g., ball-in-cage)	3.0
Mechanical mitral valve replacement	3.0
On-X mechanical AVR, no thromboembolic risk factors, starting ≥3 months post-op	1.5–2.0 (plus aspirin 75–100 mg daily)

If a patient on a mechanical valve has a thromboembolic event despite an adequate INR and good time in therapeutic range, guidance supports either raising the INR target by about 0.5, or adding low-dose aspirin (75–100 mg daily) when bleeding risk is low — rather than switching to a DOAC, which remains contraindicated regardless.

Bioprosthetic Valves

• TAVI: aspirin 75–100 mg daily is reasonable in the absence of another indication for oral anticoagulation
• Surgical bioprosthetic AVR or MVR: aspirin 75–100 mg daily is similarly reasonable
• For surgical bioprosthetic valves at low bleeding risk, a VKA targeted to an INR of 2.5 for 3–6 months after surgery is a reasonable alternative to aspirin alone
• For TAVI at low bleeding risk, either dual antiplatelet therapy (aspirin plus clopidogrel) for 3–6 months, or a VKA to INR 2.5 for at least 3 months, are reasonable alternatives
• A specific combination to avoid: low-dose rivaroxaban plus aspirin after TAVI is explicitly flagged as harmful in the ACC/AHA guideline (Class 3: No Benefit/Harm) — this is not simply “unproven,” it is actively discouraged

Follow-Up Imaging Schedule

This is genuinely useful, concrete guidance that’s easy to forget in daily practice:

• An initial postoperative TTE is recommended for every prosthetic valve or valve repair, establishing the individual patient’s baseline hemodynamics for comparison at every subsequent study — ideally under stable hemodynamic conditions, and used as the reference point for every deterioration criterion described below.
• Bioprosthetic surgical valve: TTE at 5 and 10 years, then annually thereafter, even without a change in clinical status
• Bioprosthetic TAVI: TTE annually, from the start — a notably more frequent schedule than surgical bioprosthetic valves. Long-term TAVI follow-up data show stable echocardiographic findings up to 5 years, with SVD rates around 6.6% at 5 years.
• Any new or changing symptoms or signs suggesting valve dysfunction warrant a repeat TTE regardless of where the patient is in the routine schedule, and further imaging (TEE, gated cardiac CT, or fluoroscopy) even if TTE looks normal, when suspicion remains high
• Mild leaflet thickening is often the first sign of primary bioprosthetic valve failure — recognizing this should itself prompt shortening the interval to the next follow-up study, rather than waiting for the standard 5-year mark.

Risk factors for accelerated (< 5 year) structural bioprosthetic deterioration include younger age (< 60 years) at implantation, smoking, diabetes mellitus, chronic kidney disease, and an initial mean gradient ≥ 15 mmHg — patients with these features may reasonably be considered for earlier, annual surveillance rather than waiting for the standard 5-year mark.

Formal Criteria for Structural Valve Deterioration

Beyond “the gradient went up,” the 2024 ASE guideline gives explicit, two-tier hemodynamic criteria for SVD, compared against the postprocedural baseline (defined at 1–3 months):

	Possible SVD	Significant SVD
Mean gradient	Rise ≥10 mmHg, to a resulting gradient ≥20 mmHg	Rise ≥20 mmHg, to a resulting gradient ≥30 mmHg
With concomitant EOA change	Fall ≥0.3 cm² or ≥25%	Fall ≥0.6 cm² or ≥50%
And/or DVI change	Fall ≥0.1 or ≥20%	Fall ≥0.2 or ≥40%
Regurgitation criterion	New or worsening intraprosthetic AR by ≥1 grade, to at least moderate	New or worsening intraprosthetic AR by ≥2 grades, to at least moderate-to-severe

Both tiers assume stable LV function and blood pressure, and require evident morphologic changes to the prosthesis on imaging — the numbers alone, without a visible structural change, shouldn’t be read as SVD. In the setting of combined stenosis and regurgitation, significant SVD may be present at even lower thresholds than listed here.

Echocardiographic Evaluation

General Principles (All Valve Types)

• All prosthetic valves are inherently somewhat stenotic compared to a native valve — expected gradients vary by valve type, size, and site, and must be interpreted against that specific valve’s expected range (available in published reference tables by manufacturer, type, and size), not native valve norms.
• Establish baseline Doppler values within the first 30 days after surgery.
• Document date of valve replacement, valve type and size, symptoms, height/weight/BSA, blood pressure, and heart rate at the time of every study — heart rate specifically affects diastolic filling time and therefore mean gradients across mitral and tricuspid prostheses, and BSA is needed to assess for prosthesis-patient mismatch.
• Average 5–10 beats for hemodynamic measurements.
• Record the transducer position that yielded the optimal Doppler signal, so the same window can be reproduced on follow-up studies for a valid comparison — and always compare against the individual patient’s own prior studies, not population reference values alone, when dysfunction is suspected.
• Zoom imaging with multiple views is needed to evaluate every component of the prosthesis. Because of acoustic reverberation from prosthetic material, visualizing the central occluder or leaflets often requires off-axis imaging rather than standard planes alone.
• Biplane imaging allows simultaneous real-time assessment of valve structure and color Doppler localization of paravalvular regurgitation.
• A specific pitfall with stentless valves: aortic root thickening from hematoma and edema after implantation usually resolves over 3 to 6 months, but can be mistaken for an aortic root abscess in the interim — reviewing the immediate postoperative or intraoperative study helps confirm this benign explanation rather than raising a false alarm for infection.
• 3D echocardiography should image the prosthesis with and without color Doppler, using whichever view best shows the valve or paravalvular structures; the en face view is particularly useful for localizing paravalvular leak and guiding percutaneous intervention. Single-beat acquisition is preferred when feasible; multibeat acquisition may be needed specifically when 3D color Doppler is required to quantify vena contracta area, since this improves line density and volume rate.

M-Mode

Limited use for prosthetic valves overall. Leaflet thickness > 3 mm, or coarse fluttering, is abnormal.

2D Echocardiography

Visualizes leaflet motion, calcification, thrombus, vegetation, and dehiscence, and allows assessment of LV function. For mechanical valves specifically, 2D imaging is limited by reverberation artifact from the prosthetic material — TEE is often needed for adequate clarity, and if precise leaflet or occluder motion needs to be resolved (for example, when valve obstruction or PPM is a genuine question), dedicated radiologic imaging with CT or fluoroscopy is advised rather than relying on echo alone.

Determining Gradients: The Bernoulli Correction Most People Forget

The simplified Bernoulli equation (ΔP = 4V²) is the standard approach — but when the proximal (LVOT) velocity exceeds 1.5 m/s, as can occur with high cardiac output or a narrow LVOT, it can no longer be ignored, and the gradient should instead be calculated as ΔP = 4(V₂² − V₁²). This correction matters most for aortic prostheses in exactly the clinical settings — high output, small LVOT — where an inflated gradient could otherwise be misread as valve stenosis.

EOA and DVI: The Flow-Independent Parameters

EOA = stroke volume ÷ VTI through the prosthetic valve. For stroke volume via the LVOT, the diameter measurement is the largest source of error — it should always be the largest diameter measured perpendicular to the LVOT, not an averaged value, since the error runs toward underestimating the diameter. For surgical AVR, measure just below the valve plane; for TAVI, use the outer-to-outer diameter of the stented valve, with the PW sample volume placed apical to the stent frame at peak systole (using the inner-to-inner diameter with a matched sample volume within the stent risks capturing flow acceleration and overestimating stroke volume). Never use the prosthesis’s labeled size to calculate annular area — this is explicitly not recommended. Biplane or 3D LV volumes are useful alternatives when LVOT flow acceleration is present, and ultrasound-enhancing agents are recommended to avoid the LV stroke volume underestimation that’s otherwise common with echocardiography compared to CMR.

DVI (Doppler velocity index) is the ratio of VTI proximal to the valve to VTI through the valve — flow- independent, and therefore complementary to velocity/gradient rather than redundant with them. DVI ≤0.35 is associated with adverse outcomes for surgical AVR, but not for TAVI — a genuinely position-specific threshold. The inverse ratio is used for prosthetic mitral valves, where it also helps flag significant mitral regurgitation, since MR increases flow through the mitral valve while decreasing flow through the LVOT. Significant stenosis should be confirmed with at least one flow-dependent parameter (velocity, mean gradient) and at least one flow-independent parameter (EOA or DVI) together — neither category alone is considered sufficient.

Prosthesis-Patient Mismatch: Position-Specific Thresholds

PPM occurs when a normally functioning prosthesis — normal EOA, normal leaflet mobility — is simply too small relative to the patient’s body size and resting flow needs, producing a high gradient and functional stenosis. Gradients can be deceptively normal in the setting of PPM combined with low flow — an entity independently associated with poor outcomes, and a reason not to rule out PPM purely because the gradient looks unremarkable.

• Aortic PPM: diagnosed by indexed EOA (EOA ÷ BSA). Gradients rise exponentially once indexed EOA falls below 0.8–0.9 cm²/m². Moderate PPM occurs in 20–70% of SAVR patients and severe PPM in 2–20%; TAVI has a lower rate of severe PPM than SAVR. Indexed EOA — not prosthesis size or geometric specification — is the only parameter consistently tied to postoperative gradients and clinical outcomes. Indexed EOA can overestimate PPM severity in obesity (BMI > 30 kg/m²), and different thresholds are suggested for these patients. PPM is associated with reduced exercise capacity, lower functional class, decreased short- and long-term survival, higher heart failure and hospitalization rates, less regression of LV hypertrophy, and faster subsequent SVD. Worse outcomes cluster in patients under 65–70 years old and those with LV dysfunction, significant hypertrophy, low-flow low-gradient aortic stenosis, or coexisting MR. PPM can often be avoided altogether by calculating the projected indexed EOA before implantation and, when mismatch is anticipated, choosing an alternative prosthesis, opting for TAVI, or considering aortic root enlargement surgery.
• Mitral PPM: the correlation between indexed EOA and transvalvular gradient is weaker than in the aortic position, but mismatch still occurs and may be underdiagnosed. Thresholds are notably higher than aortic: an ideal indexed EOA is > 1.2 cm²/m²; moderate mitral PPM is under 1.2 cm²/m², and severe mitral PPM is ≤ 0.9 cm²/m². Reported prevalence is substantial — 39–71% — and mitral PPM is associated with persistent pulmonary hypertension and reduced perioperative and long-term survival, with clinical outcomes that may actually be worse than aortic PPM, particularly under age 70. It can be minimized by choosing a prosthesis with a larger projected EOA when feasible. Calculating mitral EOA by the pressure half-time method is discouraged here specifically because it frequently overestimates EOA, especially in normal valves — the continuity equation is the preferred approach.

Doppler — By Valve Position

Aortic (SAVR) — three-tier criteria (normal / possible stenosis / suggests significant stenosis):

Parameter	Normal	Possible stenosis	Significant stenosis
Jet contour	Triangular, early-peaking	Triangular to intermediate	Rounded, symmetric
Acceleration time	Under 80 ms	80–100 ms	Over 100 ms
AT/ejection time ratio	Under 0.32	0.32–0.37	Over 0.37
Peak velocity	Under 3 m/s	3–4 m/s	4 m/s or more
Mean gradient	Under 20 mmHg	20–34 mmHg	35 mmHg or more
DVI	Over 0.35	0.25–0.35	Under 0.25
EOA	Within 1 SD of the reference value	1 SD smaller than reference	2 SDs smaller than reference

Aortic (TAVI) — graded by change from the individual patient’s own stable-hemodynamic baseline, not absolute values:

Parameter	Normal	Possible stenosis	Significant stenosis
Mean gradient	Change under 10 mmHg	Increase of 10–19 mmHg	Increase of 20 mmHg or more
DVI	Change under 0.1 or 20%	Decrease of 0.1–0.19 or 20–39%	Decrease of 0.2 or more, or 40% or more
EOA	Change under 0.3 cm² or 25%	Decrease of 0.3–0.59 cm² or 25–49%	Decrease of 0.6 cm² or more, or 50% or more

For TAVI specifically, in-stent flow acceleration occurs at two locations (below the valve and at the level of the cusps), so LVOT measurements must be taken proximal to the stent to avoid overestimating EOA. Compared with SAVR, TAVI tends to show similar or lower gradients, higher indexed EOA, and lower PPM rates, but a higher prevalence of mild aortic regurgitation postprocedurally. After valve-in-valve TAVI, moderate-or-greater PPM occurs in about 60% of patients and severe PPM in about 25% — though this does not appear to affect 1- or 3-year mortality — and an elevated mean gradient (>20 mmHg) occurs in about 28% of ViV patients.

Mitral (both mechanical and bioprosthetic) — current criteria for significant stenosis, genuinely stricter and more specific than the equivalent thresholds used for native mitral stenosis: mean gradient above 10 mmHg at a normal heart rate, PHT above 200 ms, DVI above 2.5, and EOA under 1 cm² — with DVI shown to be the most sensitive and specific single parameter for stenosis in one study. Reference hemodynamics differ meaningfully by valve type: mechanical mitral valves typically have an EOA of 2–3 cm² and a mean gradient of 2–3 mmHg (some smaller valves up to 5–6 mmHg at physiologic heart rates); bioprosthetic mitral valves typically have an EOA of 2.2–3.5 cm² and a mean gradient of 3–5 mmHg. Bileaflet mechanical mitral valves are also subject to the same pressure-recovery phenomenon described above, tending to slightly overestimate gradient and underestimate EOA.

Indirect signs suggesting significant mitral regurgitation — genuinely useful when direct jet visualization is limited by prosthesis shadowing, which it frequently is:

1. A dense CW MR jet
2. Elevated mitral E velocity (> 1.9 m/s specifically in mechanical valves)
3. Low systemic output and LVOT VTI despite a hyperdynamic-appearing left ventricle
4. An elevated VTI (prosthetic mitral valve ÷ LVOT) ratio, above 2.5
5. A large zone of systolic flow convergence on the LV side of the prosthesis
6. A significant rise in PA pressure compared with a previous study

A perivalvular leak is always considered abnormal and warrants further investigation, regardless of how small it appears — and the parasternal window is often the optimal view for prosthetic mitral regurgitant jets specifically, with apical views more useful for an eccentric or paravalvular jet, or for visualizing leaflet vegetation, thrombus, or pannus.

Tricuspid:

• Bioprosthetic TV obstruction is suggested by a CW E-wave velocity ≥ 2.1 m/s (in the absence of tachycardia); mechanical TV obstruction is suggested at a lower threshold, ≥ 1.9 m/s.
• Mean gradient under 6–9 mmHg has been associated with normal bioprosthetic TV function across a range of prostheses; under 6 mmHg specifically marks normal mechanical TV function. Remember that valve size and high-output states can independently affect mean gradient even without true dysfunction.
• After valve-in-valve or valve-in-ring tricuspid procedures, a postimplantation mean gradient > 10 mmHg is itself considered evidence of stenosis.
• Bioprosthetic TV degeneration occurs in about 0.4–2.2% of patients per year, with freedom from bioprosthetic TV dysfunction around 66% at 5 years — meaningfully lower durability than other positions. Mechanical TV thrombosis rates run 0.5–3.3% per year, consistent with the markedly elevated right-sided thrombosis risk noted above.
• For TR severity: a large central color jet (area > 10 cm²), a vena contracta width ≥ 0.7 cm, a PISA radius

  0.9 cm, or an EROA ≥ 0.4 cm² (versus < 0.2 cm² for usually-mild TR) each suggest severe regurgitation — shift the baseline Nyquist limit to 25–35 cm/s for PISA in this setting, the same technique described for native tricuspid regurgitation. RA and RV dilation typically accompanies significant TR, though left heart disease and pulmonary hypertension can independently cause the same chamber dilation, and changes in RA compliance after TVR frequently blunt or delay hepatic vein flow reversal — so these supportive signs need the same cautious interpretation as with native tricuspid regurgitation.

Pulmonic:

• Abnormal: peak velocity > 2.5 m/s
• Look for abnormal regurgitant jets or leaks — the DVI concept can also be applied here, though with less validation than in the aortic or mitral positions.

TTE and TEE Are Complementary, Not Interchangeable

This is worth understanding rather than just remembering “TEE is better” (see Transesophageal Echocardiography for the standard views used to interrogate prosthetic valves):

• Prosthetic mitral valves — the left atrial side of the prosthesis is acoustically shadowed on TTE, reducing sensitivity for prosthetic mitral regurgitation, thrombus, pannus, or vegetation on that side specifically. TEE provides much better visualization of the LA side and is more accurate for diagnosing prosthetic mitral valve dysfunction. Three-dimensional TEE has a particularly important role for prosthetic mitral pathology, given the proximity of the valve to the LA and the achievable en face view of the entire valve.
• Prosthetic aortic valves — the posterior aspect is shadowed on TTE, while the anterior aspect is shadowed on TEE. Both studies are genuinely needed for a complete assessment of a prosthetic aortic valve — neither view alone reliably sees the whole valve. Adjusting the TEE probe’s imaging angle or depth can partially “shift” the artifact to allow visualization of otherwise-obscured segments, and transgastric images add real value for assessing leaflet motion, gradient, and regurgitation from a different angle — though Doppler alignment from the transgastric approach may not be optimal.
• TEE has superior sensitivity for vegetations and abscess in suspected prosthetic valve (or annuloplasty ring) endocarditis.
• With suspected mechanical valve obstruction, fluoroscopy or cardiac CT can add useful information about reduced leaflet/occluder motion from pannus ingrowth or thrombus, complementing the echocardiographic findings — normal mechanical leaflet opening angles are roughly 73–90° for bileaflet valves and 60–80° for monoleaflet valves, useful reference figures when CT is used to assess leaflet motion directly.

Stress Echocardiography

Useful when there’s a discrepancy between resting valve hemodynamics and the patient’s symptoms — normally and abnormally functioning prosthetic valves can look similar at rest, so a normal resting study doesn’t rule out a real, exertional problem. Symptoms in this setting can stem from prosthetic stenosis, prosthetic regurgitation, PPM, coronary disease, or pulmonary disease, and stress testing helps distinguish between them. Because hemodynamics can normalize quickly after treadmill exercise, supine bicycle exercise or pharmacologic stress with dobutamine are generally preferred over treadmill protocols specifically so that valvular hemodynamics can be captured during and at peak stress, though exercise (when feasible) is generally favored over pharmacologic stress for its more physiologic response. The overall approach to assessing valve obstruction under stress mirrors that used for native valve stenosis — see Aortic Stenosis for the broader stress-echo framework this builds on.

Key Considerations Across Both Valve Types

• Hemodynamics: prosthetic valves inherently carry higher gradients than the native valve they replaced — always interpret findings against that specific prosthesis’s expected range, with heart rate, blood pressure, and ventricular function documented alongside, and remember that pressure recovery and the modified Bernoulli correction can both meaningfully affect what a given gradient actually means.
• Consistency on follow-up: use the same imaging technique and transducer position across serial studies whenever possible, since this is what makes longitudinal comparison — and the formal SVD criteria above — meaningful.
• Infective endocarditis: early diagnosis via TEE is critical in a symptomatic patient with a prosthetic valve — see the Infective Endocarditis tutorial for the broader diagnostic framework, which applies here too.
• Perivalvular leaks are always considered abnormal and require investigation, regardless of how small they appear — though in the immediate postoperative period, a small paravalvular leak (seen in 5–20% of patients right after implantation) is usually clinically and hemodynamically insignificant and follows a benign course in the absence of endocarditis.